Organ transplantation has within the previous couple of decades become an efficient sort of treatment for end stage heart, liver and renal failure, and therefore the technical skill and knowledge for transplantation of other organs just like the lung and pancreas are being continuously developed. Our ability to regulate the transplant patient’s immune reaction and therefore the side effects of unimpressive regimens has reduced the incidence of acute graft loss. Along the way, issues concerning live donors, particularly in liver transplantation, have also emerged within the context of non-maleficence of live donors who run the danger of mortality and physical and psychological morbidity.  Solid organ transplantation is one such advance which has generated and continues to get issues involving ethics, law and morality. Organ transplantation has become an efficient sort of treatment particularly for end stage heart, liver and renal failure. Except for renal failure, organ transplantation is that the only sort of possible treatment for the opposite organ failure states, just like the heart or the liver. The success rate in solid organ transplantation generally has improved since the primary heart transplant 40 years ago, and this is often as a result of our ability to regulate the transplant patient’s immune response. This has reduced the incidence of acute graft loss and therefore the side effects of unimpressive regimens and given greater confidence among transplant surgeons who now believe that organ transplantation should no more be reserved for life-threatening organ failure but should even be available for structural non-life-threatening defects.